|
|
|
| |
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms ( ), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
TT-103MH is a new recombinant protein developed for use in the treatment of non-life threatening mild-to-severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliacs. It has been observed to prevent death in a lethal model of hemophilia in mice; TT-103MH also reduced blood coagulation time up to 90% in ex vivo studies using hemophiliac blood.
We have developed High Throughput Screening Pathway Activity named BioplatformScreen TM. A new High Through Screening Phatway Activity (HTS-PA) family raise, HemostaBioplatformScreen, OxidantBioplatformScree and AtheroBioplatformScreen.
Novel and significantly radical approach for the treatment of bleeding disorders, using a topical formulation. See all antihemorrhagic information of new discover TT-103MH for bleeding disorders.
Know the novel hemostatic drug generation TT-103MH got through BioplatformScreen by Thrombotargets. For topical treatment of bleeding disorders.
|
|
|
|
